

Quantity Limit; Post Limit Prior Authorization Journavx

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Journavx	suzetrigine

Indications

FDA-approved Indications

Journavx is indicated for the treatment of moderate to severe acute pain in adults.

Initial Quantity Limit

If the patient is requesting more than the initial quantity limit, the claim will reject with a message indicating that a prior authorization is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

Initial Limit Quantity

The duration of 25 days is used for a 30-day fill period to allow time for refill processing.

Reference number(s)
6834-HJ

These drugs are for short-term acute use; therefore, the intent is for prescriptions of the requested drug to be filled one month at a time; there should be no 3 month supplies filled.

Drug	1 Month Limit	3 Month Limit
Journavx (suzetrigine)	29 tablets / 25 days	Does Not Apply

Coverage Criteria

Acute Pain

Authorization may be granted when the requested drug is being prescribed for the treatment of moderate to severe acute pain in adults.

Quantity Limits Apply

Post Limit Quantity

The duration of 25 days is used for a 30-day fill period to allow time for refill processing.

These drugs are for short-term acute use; therefore, the intent is for prescriptions of the requested drug to be filled one month at a time; there should be no 3 month supplies filled.

Medication	1 Month Limit	3 Month Limit
Journavx	58 tablets / 25 days	Does Not Apply

Duration of Approval (DOA)

- 6834-HJ: DOA: 1 month

References

1. Journavx [package insert]. Boston, MA: Vertex Pharmaceuticals Incorporated; January 2025.
2. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2025. <https://online.lexi.com>. Accessed January 31, 2025.